Matches in Nanopublications for { ?s ?p ?o <http://purl.org/np/RAnr3oEk4Cf1UeR3LLPPY0M5cjGvViPLiktjKR6yDv1Ks#assertion>. }
Showing items 1 to 9 of
9
with 100 items per page.
- association type Statement assertion.
- association label ""Eletriptan hydrobromide tablets are contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina [see Warnings and Precautions ( 5.1 )] Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions ( 5.2 )] History of stroke, transient ischemic attack (TIA), or history or current evidence of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions ( 5.4 )] Peripheral vascular disease [see Warnings and Precautions ( 5.5 )] Ischemic bowel disease [see Warnings and Precautions ( 5.5 )] Uncontrolled hypertension [see Warnings and Precautions ( 5.8 )] Recent use (i.e., within 24 hours) of another 5-hydroxytryptamine 1 1 [see Drug Interactions ( 7.1 )] Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) [see Warnings and Precautions ( 5.9 )] Recent use (i.e., within at least 72 hours) of the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir [see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 )] History of coronary artery disease (CAD) or coronary artery vasospasm ( 4 Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders ( 4 History of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine ( 4 Peripheral vascular disease ( 4 Ischemic bowel disease ( 4 Uncontrolled hypertension ( 4 Within 24 hours of treatment with another 5-HT 1 4 Hypersensitivity to eletriptan hydrobromide tablets (angioedema and anaphylaxis seen) ( 4 Within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir ( 4"" assertion.
- association subject drugbank:DB00216 assertion.
- association predicate treats assertion.
- association object DOID_3393 assertion.
- association relation MedicalContraindication assertion.
- DOID_3393 category Disease assertion.
- drugbank:DB00216 category Drug assertion.
- association provided_by NeuroDKG assertion.